Despite an already strong run, ADMA Biologics, Inc. (NASDAQ:ADMA) shares have been powering on, with a gain of 53% in the last thirty days. The annual gain comes to 136% following the latest surge, making investors sit up and take notice.
Even after such a large jump in price, ADMA Biologics may still be sending buy signals at present with its price-to-sales (or "P/S") ratio of 7.9x, considering almost half of all companies in the Biotechs industry in the United States have P/S ratios greater than 12.2x and even P/S higher than 66x aren't out of the ordinary. However, the P/S might be low for a reason and it requires further investigation to determine if it's justified.
NasdaqGM:ADMA Price to Sales Ratio vs Industry May 22nd 2024
How Has ADMA Biologics Performed Recently?
Recent times haven't been great for ADMA Biologics as its revenue has been rising slower than most other companies. It seems that many are expecting the uninspiring revenue performance to persist, which has repressed the growth of the P/S ratio. If this is the case, then existing shareholders will probably struggle to get excited about the future direction of the share price.
If you'd like to see what analysts are forecasting going forward, you should check out our free report on ADMA Biologics.
What Are Revenue Growth Metrics Telling Us About The Low P/S?
There's an inherent assumption that a company should underperform the industry for P/S ratios like ADMA Biologics' to be considered reasonable.
Taking a look back first, we see that the company grew revenue by an impressive 56% last year. Spectacularly, three year revenue growth has ballooned by several orders of magnitude, thanks in part to the last 12 months of revenue growth. Accordingly, shareholders would have been over the moon with those medium-term rates of revenue growth.
Turning to the outlook, the next three years should generate growth of 20% per year as estimated by the four analysts watching the company. That's shaping up to be materially lower than the 211% per annum growth forecast for the broader industry.
With this information, we can see why ADMA Biologics is trading at a P/S lower than the industry. Apparently many shareholders weren't comfortable holding on while the company is potentially eyeing a less prosperous future.
The Bottom Line On ADMA Biologics' P/S
ADMA Biologics' stock price has surged recently, but its but its P/S still remains modest. Generally, our preference is to limit the use of the price-to-sales ratio to establishing what the market thinks about the overall health of a company.
We've established that ADMA Biologics maintains its low P/S on the weakness of its forecast growth being lower than the wider industry, as expected. Right now shareholders are accepting the low P/S as they concede future revenue probably won't provide any pleasant surprises. It's hard to see the share price rising strongly in the near future under these circumstances.
We don't want to rain on the parade too much, but we did also find 1 warning sign for ADMA Biologics that you need to be mindful of.
If these risks are making you reconsider your opinion on ADMA Biologics, explore our interactive list of high quality stocks to get an idea of what else is out there.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
儘管ADMA Biologics, Inc.(納斯達克股票代碼:ADMA)的股價已經表現強勁,但在過去的三十天裏,其股價仍然上漲了53%。在最近的飆升之後,年漲幅達到136%,這使投資者坐下來注意了。
即使在價格大幅上漲之後,ADMA Biologics目前仍可能以7.9倍的市銷率(或 “市銷率”)發出買入信號,因爲美國生物技術行業幾乎有一半公司的市銷率超過12.2倍,甚至市盈率高於66倍也並非不尋常。但是,市銷率低可能是有原因的,需要進一步調查以確定其是否合理。
納斯達克通用汽車公司:ADMA 與行業的股價銷售比率 2024 年 5 月 22 日
ADMA 生物製劑最近的表現如何?
最近對ADMA Biologics來說並不是一件好事,因爲其收入的增長速度比大多數其他公司都要慢。看來許多人預計平淡無奇的收入表現將持續下去,這抑制了市銷率的增長。如果是這樣的話,那麼現有股東可能很難對股價的未來走向感到興奮。
如果你想了解分析師對未來的預測,你應該查看我們關於ADMA Biologics的免費報告。
收入增長指標告訴我們低市銷率有哪些?
人們固有的假設是,如果像ADMA Biologics這樣的市銷率被認爲是合理的,公司的表現應該低於該行業。
首先回顧一下,我們發現該公司去年的收入增長了令人印象深刻的56%。引人注目的是,三年的收入增長激增了幾個數量級,這在一定程度上要歸功於過去12個月的收入增長。因此,有了這些中期收入增長率,股東們就會大吃一驚。
展望來看,根據關注該公司的四位分析師的估計,未來三年將實現每年20%的增長。這將大大低於整個行業預期的211%的年增長率。
有了這些信息,我們可以了解爲何ADMA Biologics的市銷售率低於該行業。顯然,許多股東不願堅持下去,而該公司可能正在考慮不那麼繁榮的未來。
ADMA Biologics 市銷率的底線
ADMA Biologics的股價最近飆升,但其市銷率仍然不高。通常,我們傾向於限制使用市銷率來確定市場對公司整體健康狀況的看法。
我們已經確定,ADMA Biologics維持了較低的市銷率,原因是其預期的增長低於整個行業,正如預期的那樣。目前,股東們正在接受低市銷率,因爲他們承認未來的收入可能不會帶來任何驚喜。在這種情況下,很難看到股價在不久的將來強勁上漲。
我們不想在遊行隊伍中下太多雨,但我們也找到了一個需要注意的ADMA Biologics警告標誌。
如果這些風險讓你重新考慮你對ADMA Biologics的看法,請瀏覽我們的高質量股票互動清單,了解還有什麼。
對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接聯繫我們。或者,也可以發送電子郵件至編輯團隊 (at) simplywallst.com。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。